Literature DB >> 15254687

Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma.

Lian-Wen Yuan1, Wei Tang, Norihiro Kokudo, Yasuhiko Sugawara, Hirona Karako, Kiyoshi Hasegawa, Taku Aoki, Yusuke Kyoden, Geertu Deli, Yong-Guo Li, Masatoshi Makuuchi.   

Abstract

In a recent experiment, we discovered that liver tissue adjacent to HCC can also produce des-gamma-carboxy prothrombin (DCP). The goal of this study was to advance measurements of DCP levels in hepatocellular carcinoma (HCC) and non-cancer tissues using an electro-chemiluminescence immunoassay (ECLIA) and immunohistochemistry, and to assess their clinical significance. DCP levels in HCC tissues ranged from 0.7 to 209862.4 mAU/0.1 g tissue weight, with a median of 492.6 mAU/0.1 g. DCP levels in non-cancer tissues ranged from 0 to 2329.9 mAU/0.1 g tissue weight, with a median of 88.8 mAU/0.1 g. DCP levels in cell membranes were significantly higher than in the cytoplasm (p<0.001). DCP levels in HCC tissue were significantly higher than in non-cancer tissue (p<0.001). The logarithm of serum DCP levels correlated not only with that of DCP levels in HCC tissues (p=0.019), but also with that in non-cancer tissues (p=0.020), and the total DCP level of liver tissues (p=0.016). The logarithm of DCP levels in HCC tissues correlated with that of DCP levels in non-cancer tissues (p=0.011). DCP levels in HCC tissue with portal vein invasion were significantly greater than in HCC tissues without portal vein invasion (p=0.028). DCP levels in non-cancer tissues with intrahepatic metastatic lesions were significantly higher than in non-cancer tissues without intrahepatic metastatic lesions (p=0.023). Our results suggest that the origin of elevated serum DCP may lie not only in HCC tissue, but in non-cancer tissue. The existence of HCC may influence production of DCP in non-cancer tissue. Tissue DCP may be a prognostic factor, while increased DCP levels in non-cancer tissues may play an important role in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254687

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

Review 1.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

2.  Upregulation of des-gamma-carboxy-prothrombin after portal vein embolization in a cirrhotic patient with hepatocellular carcinoma.

Authors:  Tetsuro Sohda; Kaoru Iwata; Akira Anan; Hideo Kunimoto; Kaoru Yotsumoto; Keiji Yokoyama; Daisuke Morihara; Yasuaki Takeyama; Satoshi Shakado; Akinobu Osame; Shinichi Kora; Jun Ohishi; Yasushi Yamauchi; Tomoaki Noritomi; Kengo Yoshimitsu; Yuichi Yamashita; Shotaro Sakisaka
Journal:  Clin J Gastroenterol       Date:  2015-09-15

Review 3.  A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma.

Authors:  Ji De; Yi Shen; Jinyu Qin; Li Feng; Yiping Wang; Li Yang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

4.  Treatment outcomes of spontaneous rupture of hepatocellular carcinoma with hemorrhagic shock: a multicenter study.

Authors:  Feng Zhong; Xin-Sheng Cheng; Kun He; Shi-Bo Sun; Jie Zhou; Hai-Ming Chen
Journal:  Springerplus       Date:  2016-07-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.